Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

121.86 +0.20 (+0.16%)

Official Closing Price Updated: 7:00 PM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	8,933,340
Open	121.40
Bid (Size)	121.50 (100)
Ask (Size)	123.00 (300)
Prev. Close	121.66
Today's Range	120.50 - 122.60
52wk Range	73.31 - 123.33
Shares Outstanding	2,531,374,696
Dividend Yield	2.79%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

Today 10:03 EST

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...

Via Finterra

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Today 5:15 EST

From Merck & Co., Inc.

Via Business Wire

Performance

YTD	+14.5%	+14.5%
1 Month	+11.3%	+11.3%
3 Month	+28.3%	+28.3%
6 Month	+41.6%	+41.6%
1 Year	+42.4%	+42.4%

More News

Merck & Co. Inc. (NYSE:MRK) Emerges as a Strong Dividend Contender Through Methodical Screening ↗

Today 4:41 EST

Via Chartmill

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

February 18, 2026

From Merck & Co., Inc. and Mayo Clinic

Via Business Wire

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

Via Finterra

Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗

February 17, 2026

Via Stocktwits

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Via MarketMinute

8 Cheap Stocks to Buy in 2026 ↗

February 16, 2026

Via The Motley Fool

2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗

February 14, 2026

Via The Motley Fool

Prediction: These Could Be the Best-Performing Value Stocks Through 2030 ↗

February 14, 2026

Via The Motley Fool

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

February 13, 2026

Via MarketMinute

Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗

February 13, 2026

Via The Motley Fool

Dow Jones 267-Point Slide: Blue-Chip Leaders and the AI Reality Check

February 13, 2026

Via MarketMinute

3 Mega-Cap Stocks for Long-Term Investors

February 12, 2026

Via StockStory

The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle

February 12, 2026

Via MarketMinute

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

Via MarketMinute

Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market

February 12, 2026

Via Finterra

The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation

February 12, 2026

Via Finterra

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

February 12, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

February 11, 2026

From Merck & Co., Inc.

Via Business Wire

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

Via MarketMinute

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Via Finterra

5 Revealing Analyst Questions From Merck’s Q4 Earnings Call

February 10, 2026

Via StockStory

Stock Market Today, Feb. 9: Oracle Climbs on AI Optimism Despite Software Sector Weakness ↗

February 09, 2026

Via The Motley Fool

3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 ↗

February 08, 2026

Via The Motley Fool

Frequently Asked Questions

Is Merck & Co publicly traded?

Yes, Merck & Co is publicly traded.

What exchange does Merck & Co trade on?

Merck & Co trades on the New York Stock Exchange

What is the ticker symbol for Merck & Co?

The ticker symbol for Merck & Co is MRK on the New York Stock Exchange

What is the current price of Merck & Co?

The current price of Merck & Co is 121.86

When was Merck & Co last traded?

The last trade of Merck & Co was at 02/19/26 07:00 PM ET

What is the market capitalization of Merck & Co?

The market capitalization of Merck & Co is 308.47B

How many shares of Merck & Co are outstanding?

Merck & Co has 308B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.